Pre-market: Critical Therapeutics gets FDA approval
Lexington, Mass.-based Critical Therapeutics, Inc. (Nasdaq: CRTX) announced this morning that the U.S. Food and Drug Administration approved its drug for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Nevertheless, shares are down $0.03, or 2%, to $1.65.
[ More ยป ]
End-to-end electronics manufacturing services SMTC Corp. (Nasdaq: SMTX) reported this morning that its first-quarter net income was $2.8 million, or $0.19 per share, approximately three times net income reported in the first quarter 2006. Analysts were expecting earnings of $0.05 per share. The Canadian company’s stock is up $0.03, or 1%, to $3.07. spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer
|
Research
|
